U.S. markets close in 3 hours 55 minutes

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1500-0.0200 (-11.76%)
As of 09:31AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1700
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range0.1500 - 0.1500
52 Week Range0.1300 - 4.0000
Avg. Volume11,725
Market Cap7.434M
Beta (5Y Monthly)0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.1840
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EMMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Daily – Vickers Top Insider Picks for 03/21/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • PR Newswire

    Emmaus Life Sciences Announces Collaboration with Kier (Junior) Spates to Share Personal Experience with Sickle Cell Disease and Endari®

    Emmaus Life Sciences, Inc. (OTCQX: EMMA) a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced a collaboration with the Steve Harvey Morning Show cast member Kier (Junior) Spates to share Mr. Spates' personal experience with the use of Endari®, Emmaus' prescription L-glutamine oral powder, to treat his sickle cell disease, or SCD.

  • PR Newswire

    Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

  • Zacks Small Cap Research

    EMMA: A Stock with Upside Potential

    By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT Emmaus Life Sciences, Inc. (OTC:EMMA) is expanding the reach of Endari, its treatment for sickle cell disease, while also pursuing other treatments to add to its portfolio. The company had shown the ability of bringing a treatment to commercialization and we believe the market is not fully recognizing the potential Emmaus has to